Burnaby, Canada

Jinyue Ding

USPTO Granted Patents = 8 

 

Average Co-Inventor Count = 5.7

ph-index = 2

Forward Citations = 10(Granted Patents)


Company Filing History:


Years Active: 2020-2025

Loading Chart...
Loading Chart...
8 patents (USPTO):Explore Patents

Title: Jinyue Ding: Innovator in Ophthalmology and Pharmacology

Introduction

Jinyue Ding is a prominent inventor based in Burnaby, Canada. He has made significant contributions to the fields of ophthalmology and pharmacology, holding a total of 8 patents. His work focuses on developing novel compounds and methods for treating various eye diseases and disorders.

Latest Patents

Ding's latest patents include innovative compounds such as bicyclic carboxamides, which are designed to modulate the activity of EP and EP receptors. These compounds aim to treat, prevent, and ameliorate symptoms related to diseases associated with these receptors. Additionally, he has developed carbocyclic prolinamide derivatives, which are useful in preventing and treating age-related macular degeneration (AMD) and other related eye diseases. These compounds act as inhibitors of HTRA1, providing therapeutic benefits in managing various conditions.

Career Highlights

Throughout his career, Jinyue Ding has worked with notable companies such as Orion Ophthalmology LLC and Tempest Therapeutics, Inc. His expertise in the field has led to the development of groundbreaking treatments that address critical health issues.

Collaborations

Ding has collaborated with talented individuals in his field, including Robert Gomez and Renata Marcella Oballa. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Jinyue Ding's innovative work in ophthalmology and pharmacology has made a significant impact on the treatment of eye diseases. His contributions continue to shape the future of medical research and therapeutic development.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…